๐ฌ Current Disease Focus:
Task Progress: 0%
๐ฅ Active Problem Solvers
0
๐ Experts collaborating globally
โก Current Task Assignment
๐งฌ Genetic Analysis
๐ Matching experts to specific tasks
๐ Resource Allocation by Research Phase:
๐ Data Analysis
๐งช Experimental Design
๐ฌ Clinical Trials
๐ Treatment Development
The goal of this prospective study is to explore the safety and preliminary...
Status
Recruiting
Location
Fudan University Shanghai Cancer Center
Start Date
2025-01-15
Trial ID
NCT06775743
Treatments Being Tested
This is a phase II Randomized comparison clinical trial of activated CIK ar...
Status
Withdrawn
Location
Institutional Review Board of Guangzhou Fuda Cancer Hospital
Start Date
2018-04-10
Trial ID
NCT03540199
Treatments Being Tested
This is an investigator-initiated, multi-center, open-label clinical study ...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2024-07-31
Trial ID
NCT06528249
This is a prospective, multicentre, cohort study. For cohort 1(CGA cohort),...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2024-11
Trial ID
NCT06665087
This is a multicenter, double-blind, randomized, phase 2 trial to investiga...
Status
Recruiting
Location
The fourth hospital of Hebei Medical University
Start Date
2024-11-15
Trial ID
NCT06576921
Treatments Being Tested
This first-in-human open-label, multi center, dose-escalation and expansion...
Status
Terminated
Location
Liverpool Hospital
Start Date
2021-10-29
Trial ID
NCT05073484
This is a randomized, prospective, multicenter, open-label, Phase III clini...
Status
Active Not Recruiting
Location
Sir Run Run Shao hospital
Start Date
2024-07-29
Trial ID
NCT06507371
The main purpose of this research study is to determine the maximum tolerab...
Status
Active Not Recruiting
Location
University of Rochester
Start Date
2020-11-23
Trial ID
NCT04477343
Treatments Being Tested
This is a Phase 1/2 study of the combination of Ad-p53 administered intra-a...
Status
Terminated
Location
MD Anderson Cancer Center
Start Date
2018-11-20
Trial ID
NCT02842125
Evaluation of The Efficacy And Safety of Tislelizumab (PD-1) Monoclonal Ant...
Status
Unknown
Location
Multiple Locations
Start Date
2024-05-01
Trial ID
NCT06394791
Treatments Being Tested